All In Biotech

Drug Trial Radar · NCT06681324

Study Evaluating AZD7798 for Treatment in Crohn's Disease Patients With an Ileostomy

A Participant- and Investigator-blind, Randomized, Placebo-controlled Phase II Study to Evaluate Safety, Tolerability, and Mucosal Repair With AZD7798 in Patients With Active Ileal Crohn's Disease and an Ileostomy (CALLISTO)

Last checked: Nov 19, 2026Latest source record: Oct 28, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruiting

Status

Active, not recruiting

Enrollment

24

Actual

Start

Dec 11, 2024

Primary completion

Aug 10, 2026

Study completion Sep 3, 2027

Sponsor

Lead sponsor
AstraZenecaAstraZeneca (AZN)
Sponsor type
Industry
First posted
Nov 8, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Triple (participant, care provider, investigator)
Primary purpose
Other
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 80 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to evaluate safety, tolerability, and effect on mucosal repair of AZD7798 compared with placebo in participants with active ileal Crohn's disease and an ileostomy.

Conditions

  • Crohn's Disease

Interventions

  • AZD7798Drug

    AZD7798

  • PlaceboOther

    Placebo

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of participants with adverse eventsTime frame: from Week 0 to Week 12
  2. Number of participants with abnormal Vital signs: Blood pressureTime frame: from Week 0 to Week 12
  3. Number of participants with abnormal Vital signs: Pulse rateTime frame: from Week 0 to Week 12
  4. Number of participants with abnormal values in haematology: complete blood count (CBC)Time frame: from Week 0 to Week 12
  5. Number of participants with abnormal values in haematology: white blood cell (WBC) countTime frame: from Week 0 to Week 12
  6. Number of participants with abnormal values in haematology: RBCTime frame: from Week 0 to Week 12
  7. Number of participants with abnormal values in clinical chemistry: kidney functionTime frame: from Week 0 to Week 12
  8. Number of participants with abnormal values in clinical chemistry: electrolytesTime frame: from Week 0 to Week 12
  9. Number of participants with abnormal values in clinical chemistry: liver functionTime frame: from Week 0 to Week 12
  10. Number of participants with abnormal values in clinical chemistry: hs-CRPTime frame: from Week 0 to Week 12
  11. Number of participants with abnormal values in clinical chemistry: glucoseTime frame: from Week 0 to Week 12
  12. Number of participants with abnormal values in ECG readingsTime frame: from Week 0 to Week 12

Locations

17 sites in 7 countries. Site status is shown where the registry gives one.

  • Research Site

    Leuven, Belgium

  • Research Site

    Padova, Italy

  • Research Site

    Roma, Italy

  • Research Site

    Rozzano, Italy

  • Research Site

    Amsterdam, Netherlands

  • Research Site

    Nijmegen, Netherlands

  • Research Site

    Warsaw, Poland

  • Research Site

    Linköping, Sweden

  • Research Site

    Stockholm, Sweden

  • Research Site

    Kyiv, Ukraine

  • Research Site

    Kyiv, Ukraine

  • Research Site

    Vinnytsia, Ukraine

  • Research Site

    Birmingham, United Kingdom

  • Research Site

    Cambridge, United Kingdom

  • Research Site

    London, United Kingdom

  • Research Site

    London, United Kingdom

  • Research Site

    London, United Kingdom

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.